Title : Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

Pub. Date : 2016 Mar

PMID : 26894931






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 AIM: Correlation of outcomes of cyclophosphamide (CP) therapy in antineutrophil cytoplasmic antibody-associated vasculitis with genotype polymorphisms in prodrug activating cytochrome P450 enzyme genes CYP2C9 and CYP2C19. Cyclophosphamide cytochrome P450 family 2 subfamily C member 9 Homo sapiens
2 CONCLUSION: Patients with variant CYP2C9 are at increased risk for cyclophosphamide-induced leukopenia but may have a better chance to respond to treatment. Cyclophosphamide cytochrome P450 family 2 subfamily C member 9 Homo sapiens